Serum level of Total Antioxidant Status and Malondialdehyde in the Patients with Polycystic Ovarian Syndrome: a Comparative Study

Bibek Pun Magar; Dilli Pun Magar; Kapil Amgain; Keshavraj Joshi; Niranjan  Satyal; Jharendra Bahadur  Oli

doi:10.46405/ejms.v3i2.367

Bibek Pun Magar Assistant Professor, Department of Clinical Biochemistry, Karnali academy of health sciences, Jumla Nepal https://orcid.org/0000-0003-0887-6405
Dilli Pun Magar Assistant Professor, Department of Physiology, Karnali Academy of Health Sciences, Jumla, Nepal
Kapil Amgain Associate Professor, HOD of Department Clinical Anatomy, Karnali Academy of Health Sciences
Keshavraj Joshi 4 Lecturer, Department of Biochemistry, Khaptad Medical Studies and Health Sciences, Council for Technical Education and Vocational Training (CTEVT)
Niranjan Satyal Consultant Biochemist, Department of Biochemistry,Chaurjahari Municipality Laboratory, West- Rukum, Nepal
Jharendra Bahadur Oli Pathology Technician,Department of Laboratory, Royal Hobart Hospital, Australia

DOI: https://doi.org/10.46405/ejms.v3i2.367

Keywords: Antioxidants, Infertility, Oxidative biomarker, Oxidative stress, Polycystic ovary diseases, AMH, MDA, TAS, PCOD

Abstract

Background: Polycystic ovary syndrome (PCOS) is a complex endocrine disorder in women of reproductive age and a major cause of infertility. Anti- Mullerian Hormone (AMH), a valid marker of ovarian function, is used for the diagnosis of PCOS. The aim of this study is to assess the serum level of total antioxidant status (TAS) and malondialdehyde (MDA) in the premenopausal women with PCOS.

Methods: A cross-sectional analytical study was conducted at Padmashree Diagnostics, Department of Gynecology, India from April 2016 to March 2017. Census method was used to select the samples. The oxidative stress was measured by measuring the level of TAS and MDA. The data was recorded in structured proforma and and enter in SPSS version 16.0. The data were expressed in frequency, percentage, mean and standard deviation and the results obtained were analyzed using pearson’s correlation and student’s t-test. The p-value less than 0.05 was taken as statistically significant.

Results: The measured serum AMH level among the patients with PCOS was within normal range in 67.5% (27) and above normal range in 32.5% (13). The serum TAS level in normal AMH group was 814.0 + 291 µMol/L and in above normal range group was 720 + 240 µMol/L, (p <0.001). Similarly, the serum level of MDA in normal AMH group was 6.64 + 0.21 µMol/L, and in above normal range group was 8.78 + 0.22 µMol/L (p = 0.01). The measured level of AMH was significantly associated with the increased level of MDA (p<0.001) and decreased level of TAS (p<0.001). The measured MDA level in high AMH group did show statistically significant than the normal AMH group.

Conclusions: Serum level of TAS and MDA along with AMH are valuable diagnostic biomarker for the diagnosis of PCOS in the resource poor settings where ultrasound facility is unavailable.

References

Ndefo UA, Eaton A, Green MR. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. Pharmacy and therapeutics. 2013;38(6):336-55. [PubMed | Full Text | Google Scholar]

Zuo T, Zhu M, Xu W. Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxid Med Cell Longev. 2016;2016: 8589318. [PubMed | Full Text | DOI | Google Scholar]

March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–51. [PubMed | Full Text | DOI | GoogleScholar]

Luciano AA, Lanzone A, Goverde AJ. Management of female infertility from hormonal causes. Int J Gynaecol Obstet. 2013 Dec;123:S9-17. [Full Text | GoogleScholar | DOI]

Knight JA, Smith SE, Kinder VE, Anstall HB. Reference intervals for plasma lipoperoxides: age-, sex-, and specimen-related variations. Clin Chem. 1987;33(12):2289–91. [PubMed | GoogleScholar]

Kohzadi M, Khazaei MR, Choobsaz F, Khazaei M. Relationship between serum levels of anti-mullerian hormone, adiponectin and oxidative stress markers in patients with polycystic ovary syndrome. Int J Fertil Steril. 2020 Apr;14(1):27-33. doi: 10.22074/ijfs.2020.5809. [PubMed | DOI | Full Text]

Yue CY, Lu LK, Li M, Zhang QL, Ying CM. Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women. PLoS One. 2018 Aug 28;13(8):e0203129. [PubMed | GoogleScholar | Full Text]

Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated Serum Level of Anti-Mullerian Hormone in Patients with Polycystic Ovary Syndrome: Relationship to the Ovarian Follicle Excess and to the Follicular Arrest. J Clin Endocrinol Metab. 2003;88(12):5957–62. [PubMed | Full Text | DOI |GoogleScholar]

Laven JSE, Mulders AGMGJ, Visser JA, Themmen AP, De Jong FH, Fauser BCJM. Anti-Müllerian Hormone Serum Concentrations in Normoovulatory and Anovulatory Women of Reproductive Age. J Clin Endocrinol Metab. 2004;89(1):318–23. [PubMed | Full Text | DOI | GoogleScholar]

Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–70. [PubMed | Full Text | GoogleScholar]

Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol. 2005;3:1–21. [PubMed | Full Text | DOI | GoogleScholar]

Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem. 2001;34(5):407–13. [PubMed | Full Text | DOI | GoogleScholar]

Lee JY, Baw C-K, Gupta S, Aziz N, Agarwal A. Roles of Oxidative Stress in Policystic Ovary Syndrome. Serbian J Exp Clin Res. 2019;6(2):96–107. [Full Text]

Abuja PM, Albertini R. Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clin Chim Acta. 2001;306(1–2):1–17. [PubMed | Full Text | DOI |GoogleScholar]

Bachanek M, Abdalla N, Cendrowski K, Sawicki W. Value of ultrasonography in the diagnosis of polycystic ovary syndrome–literature review. J Ultrason. 2015 Dec;15(63):410-22. [PubMed | GoogleScholar | Full Text | DOI]

Sevgi R, Erdem H, Karaşahin T, et al. Determination of the relationship between serum anti‐Müllerian hormone level and superovulatory response in Simmental cows. Reprod in Domest Anim. 2019 Oct;54(10):1322-9. [PubMed | GoogleScholar | Full Text | DOI]

Woo HY, Kim KH, Rhee EJ, Park H, Lee MK. Differences of the association of anti-Müllerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocr J. 2012;59(9):781–9. [PubMed | Full Text | DOI | GoogleScholar]

Tal R, Seifer CM, Khanimov M, Seifer DB, Tal O. High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology. Reprod Biol Endocrinol. 2020 Dec;18(1):1-8. [PubMed | GoogleScholar | Full Text | DOI]

Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003;80(1):123–7. [PubMed | Full Text | DOI | GoogleScholar]

Maleedhu P, Rao P P, Kodumuri PK. Antioxidant Status in Women with Polycystic Ovary Syndrome. Res Rev J Med Heal Sci. 2014;3(Supplement 2):91–6. [PubMed | Full Text | DOI]

Fathi F. Biomarkers of Oxidative Stress in Polycystic Ovary Disorder. Ann Coll Med Mosul. 2020;41(2):112–6. [Full Text]

Verit FF, Erel O. Oxidative stress in nonobese women with polycystic ovary syndrome: Correlations with endocrine and screening parameters. Gynecol Obstet Invest. 2008;65(4):233–9. [PubMed | Full Text | DOI |GoogleScholar]

Shirsath A, Aundhakar N, Kamble P. Study of oxidative stress and antioxidant levels in polycystic ovarian disease. Int J Healthc Biomed Res. 2015;3(04):16–24. [GoogleScholar | FullText]

Mohammadi M. Oxidative stress and polycystic ovary syndrome: a brief review. Int J Prev Med. 2019;10:86. [PubMed | GoogleScholar | Full Text | DOI]

Zhang D, Luo WY, Liao H, Wang CF, Sun Y. The effects of oxidative stress to PCOS. Sichuan Da Xue Xue Bao Yi Xue Ban. 2008 May;39(3):421-3. [PubMed |GoogleScholar]

Kuşçu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2009 Jan 1;88(5):612-7. [PubMed | Full Text | DOI | GoogleScholar]

Oyebanji O, Asaolu M. Assessment of antioxidant status of women with polycystic ovarian syndrome. Asian Pacific J Reprod [Internet]. 2020;9(1):9–15. [Full Text | DOI | GoogleScholar]

Dursun P, Demirtaş E, Bayrak A, Yarali H. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS?. Hum Reprod. 2006 Jan 1;21(1):104-8. [GoogleScholar | Full Text]

Karadeniz M, Erdoǧan M, Tamsel S, Zengi A, Alper GE, Çaǧlayan O, et al. Oxidative stress markers in young patients with polycystic ovary syndrome, the relationship between insulin resistances. Exp Clin Endocrinol Diabetes. 2008;116(4):231–5. [PubMed | Full Text | GoogleScholar | DOI]